FX-322
Phase 2Small molecule
FX-322 is one of 12 small molecule programs targeting Sensorineural Hearing Loss. It is currently in Phase 2.
1
Indications
6
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Sensorineural Hearing Loss
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsApproved
Aricept
EisaiApproved
Rayos
RRoxane Laboratories
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Platelet Rich Plasma
ZZagazig University
Phase 3
Local Anesthetic
RRennes University Hospital
Phase 3
Combination
GSKPhase 1
AM-111
AAuris Medical AG
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sensorineural Hearing Loss5 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FX-322. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFrequency Therapeutics